Dimension Therapeutics

Dimension Therapeutics — Investor Presentation (January 2017)

28 slides from Dimension Therapeutics's investor presentation, Jan 31, 2017

  1. Slide 1: Dimension Therapeutics

    Exhibit 99.2 1Dimension Therapeutics

  2. Slide 2: Forward-Looking Statements

    Forward These “estimate,” timing, likelihood success our that “Risk Dimension update The 2© 2017 management we information Factors” slides or progress expected. of Dimension Looking revise of strategic Therapeutics’ “project,” and regulatory inany and contained the that, Dimension These Statements T

  3. Slide 3: Leader in Gene Therapy for Rare Liver & Metabolic Diseases

    Dimension The of Broad Leader discovering new developing for with rare associated the Manufactured Robust © 2017 the people liver diseases Leader therapeutics devastating Liver product in scientific Dimension living with Therapeutics in & Gene using pipeline AAV Therapeutics Therapy mammalian gene a

  4. Slide 4: Directed Product Platform: AAV-Based Gene Therapy

    Clade Transgene Enhanced Durable Well 25% Source: *License © 2017 population established E Dimension Gao AAV-Based expression excludes liver Cassette et al. targeting NAbs safety 2004 AAV8 Therapeutics Clade Up Gene Collaboration 2013 to JExclusive Virol; for 8ETherapy specified Capsid license hemop

  5. Slide 5: Leveraging Three Mammalian Cell Production Platforms

    Leveraging Three Regulator Well-described Serum-containing Limited HEK293 Emerging Transient Bioreactors HeLa Clonal, Well-known Similar Serum-free Large Scalable Sources: 5© 2017 Producer scale platforms high to Dimension scalability up Martin Adherent Suspension triple platform experience CHO prod

  6. Slide 6: Investing in Manufacturing Capabilities Today for Tomorrow

    Investing PD Cambridge GMP CMO Advanced Woburn CMO: 6© 2017 Engineering contract Dimension inPD/ Capabilities Tech manufacturing Therapeutics Transfer Todayorganization; for Production GMP: Access goodTomorrow manufacturing practice; PD: process development

  7. Slide 7: The Science of Liver Metabolic Disease: Believe and Proof

    The >400 Believe Proof Replicate Activity Learnings Known Restore Biomarkers, Orphan Leverage Expansion Harness Bring 7*Target © Hem Potential Other IMDs 2017 BDescribed of new larger disease drug a5-10% liver TPP: supports science learning Subset existing applied tools animal Metabolicdesignation d

  8. Slide 8: Broad Candidate Pipeline

    Broad CANDIDATE Pipeline Inherited OTC Wilson PKU GSDIa Citrullinemia* DTX301 DTX401 DTX501 DTX701 DTX601 Hemophilia DTX101 DTX201 *Citrullinemia 8© 2017 Deficiency Clinical Disease Dimension AAV8 AAVrh10 AAV Metabolic AB ASS1 Programs ATP7B SELECTION PAH FVIII type OTC G6Pase FIX Therapeutics 1Dise

  9. Slide 9: Executing 2016 Milestones, Advancing 2017+

    Executing ADVANCING Initiate GSDIa Expanded 2016 OTC Hem File PKU © 92017+ 2017 GSDIa BEU initial and US EU OTC available additional Dimension orphan Wilson IMD Key orphan data and phase 7Milestones portfolio Hem designation PROGRAM data Disease data designation 1/2 Therapeutics Atrial IND developme

  10. Slide 10: Inherited Metabolic Disease Programs

    Inherited © 2016 Dimension MetabolicTherapeutics Disease Programs

  11. Slide 11: OTC Deficiency Disease Overview

    Ornithine X-linked, Disease Genetic Adverse Treatments Patient ~10,000 Most Severe, Late Sources: © carolguze.com/text/442-11-clinical_genetics.shtml 11 2017 onset common Population early Dimension defect patients cognitive National urea Transcarbamylase inlimited, males onset cycle in UCD, WW ammon

  12. Slide 12: DTX301: Known Path to Proof of Concept

    DTX301: KNOWN Serum BIOMARKERS 13C-acetate; carbamoyl PATH US/EU Adult Sources: © 12 2017males TO ammonia; orphan Dimension DMTX-PENN DISEASE Reestablishing HPOC phosphate and ureagenesis drug at-risk neurotoxic DEFINED Therapeutics designation BIOLOGY; converted females data Ureagenesis (ASGCT to h

  13. Slide 13: DTX301: Vector and Phase 1/2 Trial Design

    DTX301: Vector DTX101 Gene Liver HEK293 TPP* Phase Open-label, Bayesian Primary (13C-acetate Up *Dosing: 13 © to cassette 2017specific targeting 91/2 capsid adult 2e12-1e13 endpoints TPP: process adaptive Phase Study safety, test) males Clade OTC Target enhancer-promoter re-establishment Dimension 1

  14. Slide 14: Glycogen Storage Disease Type Ia Overview

    Glycogen Autosomal Disease Deficient Reduced Strict Patient ~6,000 Most No Sources: Children’s © 14 2017 approved common diet Population patients Dimension Weinstein QOL, glucose-6-phosphatase Storage and Fund recessive, drug frequent GSD, long WW forDisease therapies Therapeutics etGSD term Dx ~25%

  15. Slide 15: DTX401: Known Path to Proof of Concept

    DTX401: KNOWN Improved Single Corresponding Fasting BIOMARKERS Glycogen Inability PATH Time Adult Sources: © Research 15 2017 to males TO dose blood Dimension hypoglycemia to Weinstein DISEASE Reestablishing G6Pase stores; HPOC release AAV8 and glucose reduction females build DEFINED Activity gene g

  16. Slide 16: Broad Inherited Metabolic Disease Opportunity

    Broad Wilson Citrullinemia PKU DISEASE Autosomal Deficiency OPPORTUNITY Ammonia Phenylalanine Copper BIOMARKERS ~50K 14% WW Sources: Neuro Vockley 2008; © 16 2017 of prevalence prevalent Schilsky Inherited 2014; Disease all Dimension Gen Barends BIOLOGY; UCDs in recessive Ruegger Med Type copper phe

  17. Slide 17: Hemophilia Programs

    Hemophilia © 17 2016 Dimension Programs Therapeutics

  18. Slide 18: Hemophilia B Disease Overview

    ~$6.2B Deficiency Disease Joint Frequent, Patient ~28,000 ~68% $100,000-$300,000+ Sources: shake/2014-04-02; www.ptcommunity.com/news/2014-12-29-000000/hemophilia-market-likely-undergo-major-changes; et © 18 al. 2017NEJM hemorrhages, Hem Population WW Dimension Hem Riley invasive, of B, 2007 Market

  19. Slide 19: Goal of Hemophilia Gene Therapy

    Goal Reduce Extend Durable Improve Sources: © Consistent favorable future need 19 2017 for ofbleeds, time frequency Dimension Hemophilia benefit rFIX health den effects FIX between Uijl joint replacement outcomes activity from on etof destruction Therapeutics al likelihood Gene bleeds one rFIX Haemo

  20. Slide 20: DTX101: Vector and Phase 1/2 Trial Design

    DTX101: Vector Gene Liver HEK293 TPP* Reduce Phase DTX101 Open-label, Bayesian Primary Up Dosing: *Cohorts © 20 TPP: 2017 to cassette specific targeting 12 1/2 capsid Target dependency Dimension 1.6e12-1e13 1 endpoints males process adaptive Phase Study &safety, 2Clade wild Product enhancer-promoter

  21. Slide 21: Participant Demographics and FIX Activity

    Participant 654321Patient All FIX 50-150% Bleed 5-40% Do Less Rare Frequent May <1% Bleeding Sources: © 21Low Second 2017 not patients Level frequent bleed spontaneous Severe only 70 55 53 Mild bleed Dose Dimension Information bleeds often Normal 28 48 <1.0% 2.0% Severity 1-2 Demographics as moderat

  22. Slide 22: Bleeds Before and After Dosing

    All 65432Patient Total 91Number 15 20 73% 30 33 0C 4** 12 *Data ©0ohort Low Second 2017 100% Mo Patients Number cutoff 11% 10% 5% Prior Dose 1Dimension of Cohort 12% 20% 13% 4% Bleeds* 3% Improved Post-Dose January Peak of Moderate 5% 8% 7% Moderate 2Bleeds FIX Mild Therapeutics 28, from FIX* All 20

  23. Slide 23: Clinically Asymptomatic Elevations of Liver Enzymes

    Clinically Elevations oAll *ALT: 654321Patient *Data (5e12 © IU/L 23of Patient No Low Second 2017 elevated 6elevations GC/kg) patients cutoff alanine 98 40 60 Dose Dimension 3914 52 62 22 21 39 Asymptomatic inliver 19 39 January Peak laboratory Cohort 431 6-12 in aminotransferase; ofthe enzymes ALT

  24. Slide 24: Summary of Interim Findings and Next Steps

    Summary Evidence All Notable Stable Sub-clinical, Explore Broad Multiple T Future Await © 24cell 2017 patients activation, feedback program and presentations Dimension therapeutic reduction hypotheses of of durable in high-efficiency Interim asymptomatic both of from general translational in elevati

  25. Slide 25: DTX201: Global Development Partnered with Bayer

    DTX201: A GLOBAL DEVELOPMENT $20M High R&D DMTX Bayer Partnered © 25LEADING 2017 single-digit expense to upfront, responsible Dimension fund since Global LEADER GENE subsequent reimbursement up June Collaboration toto& Therapeutics for low $232M IN 2014 THERAPY COMMERCIALIZATION preclinical HEMOPHIL

  26. Slide 26: DTX201: Sustained hFVIII Expression in Non-Human Primates

    DTX201: DTX201 hFVIII 3Seven Sustained Reduced Sources: © 26of 2017 7 animals male Expression Dimension DMTX-PENN incidence for Durable FVIII RNA cynomolgus Hem retain expression expression A FVIII in of Therapeutics expression Non anti-FVIII data macaques Expression Human in(ASGCT NHPs greater inhi

  27. Slide 27: A Leader in Liver Gene Therapy

    A Leader Dimension Liver Gene Advancing Broad Addressing Investing Strong Expected © 27 2017 Therapy Directed 7R&D Dimension program in cash Product severe, scalable, and runway manufacturing pipeline; debilitating Therapeutics Portfolio quality through multiple HeLa Focus 1Q unmet capabilities 2018

  28. Slide 28: Thank you

    Thank January © 28 2016you Dimension 2017 Therapeutics

Dimension Therapeutics — Investor Presentation (January 2017) on 6ix